Clinical Trial Details
— Status: Not yet recruiting
Administrative data
NCT number |
NCT04709848 |
Other study ID # |
20HH6406 |
Secondary ID |
|
Status |
Not yet recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
February 2021 |
Est. completion date |
December 2021 |
Study information
Verified date |
January 2021 |
Source |
Imperial College Healthcare NHS Trust |
Contact |
Paul Arkell, MBChB |
Phone |
02033113311 |
Email |
paul.arkell[@]nhs.net |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
Strongyloidiasis is a worm infection which affects more than 100 million people, mostly in
Africa, Asia and Latin America, and can cause severe illness in people with reduced immunity.
In the UK, the number of people with Strongyloides is not known.
At Imperial College Healthcare NHS Trust (ICHNT) , screening for Stongyloides has recently
been introduced as a standard-of-care for all patients undergoing BMT.
In this study, investigators will perform two cross-sectional surveys and report the
prevalence of Strongyloides in BMT recipients at ICHNT , as well as comparing clinical
outcomes before/after the introduction of routine testing.
Description:
Strongyloidiasis is a worm infection which affects more than 100 million people, mostly in
Africa, Asia and Latin America. Infection can persist for decades, and usually causes mild
symptoms. In some people with reduced immune systems (for example those who have bone marrow
transplantation), the worms can multiply and cause severe illness and death.
In the UK, the number of people with Strongyloides is not known. However, in many other
non-tropical countries, rates are high in immigrant populations (including those who are
having bone marrow transplantation, BMT).
At ICHNT, screening for Stongyloides has recently been introduced as a standard-of-care for
all patients undergoing BMT. All adult patients with forthcoming BMT at ICHNT will now be
screened. Additionally, any patients who have already undergone BMT in the last two years
will be screened as part of a look-back exercise as part of their clinical care.
In this study, investigators will perform two cross-sectional surveys. Those who underwent
BMT between Jun 2018 - July 2020 will form a 'pre-screening group', and those between July
2020 - July 2021 will form a 'screened group'. It is anticipated that 320 participants will
be included in the pre-screening group and 160 in the screened-group (total 480).
Data will be collected retrospectively and the prevalence of Strongyloides in BMT recipients
at ICHNT will be reported. Comparison of clinical outcomes between the first and second
groups will be undertaken, in order to determine whether the introduction of screening has
had an impact.